Encision Completes $80,000 Private Placement

Encision raises $80,000 from director investors for working capital through a small, restricted-share private placement.

Rhea-AI Summary

Encision (ECIA) completed an $80,000 private placement of common stock on September 8, 2026 with a group of private investors who are its directors.

The company issued 2,000,000 restricted common shares at $0.04 per share, with no registration rights, to provide funds for general working capital. After closing, Encision has 18,879,645 common shares outstanding. Encision designs and markets surgical instruments featuring its patented Active Electrode Monitoring (AEM®) technology to help prevent stray energy burns in minimally invasive surgery.

Positive

• Raises $80,000 in new capital for general working capital needs
• Directors purchase 2,000,000 restricted shares, signaling insider financial support

Negative

• Issuance of 2,000,000 new shares increases total outstanding to 18,879,645, diluting existing holders

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BOULDER, CO / ACCESS Newswire / September 11, 2026 / Encision Inc. (OTC PINK:ECIA), a medical device company owning patented Active Electrode Monitoring (AEM^®) Technology that prevents dangerous radiant energy burns in minimally invasive surgery, today announced that on September 8, 2026 it completed an $80,000 private placement of common stock with a group of private investors.

"We are pleased to have secured necessary funds for general working capital purposes," said Robert Fries, Interim President and CEO of Encision. Pursuant to the securities purchase agreement, the Company issued 2 million common shares at a per share price of $0.04 per common share. The issued shares are restricted and do not have registration rights. The investor group consisted of the Company's directors. Following the closing of the private placement, the Company has 18,879,645 total common shares outstanding.

Encision Inc. designs and markets a portfolio of high-performance surgical instrumentation that delivers advances in patient safety with AEM technology, surgical performance, and value to hospitals across a broad range of minimally invasive surgical procedures. Based in Boulder, Colorado, the company pioneered the development and deployment of Active Electrode Monitoring, AEM technology, to eliminate dangerous stray energy burns during minimally invasive procedures. For additional information about all our products, please visit www.encision.com.

In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, the Company notes that statements in this press release and elsewhere that look forward in time, which include everything other than historical information, involve risks and uncertainties that may cause actual results to differ materially from those indicated by the forward-looking statements. Factors that could cause the Company's actual results to differ materially include, among others, its ability to develop new or enhanced products and have such products accepted in the market, its ability to increase net sales through the Company's distribution channels, its ability to compete successfully against other manufacturers of surgical instruments, insufficient quantity of new account conversions, insufficient cash to fund operations, delay in developing new products and receiving FDA approval for such new products and other factors discussed in the Company's filings with the Securities and Exchange Commission. Readers are encouraged to review the risk factors and other disclosures appearing in the Company's Annual Report on Form 10-K for the year ended March 31, 2025 and subsequent filings with the Securities and Exchange Commission. We do not undertake any obligation to update publicly any forward-looking statements, whether as a result of the receipt of new information, future events, or otherwise.

CONTACT: Mala Ray, Encision Inc., 303-444-2600, mray@encision.com

SOURCE: Encision, Inc.

View the original press release on ACCESS Newswire

FAQ

Who participated in Encision's $80,000 private placement?

The investor group in the private placement consisted of the company's directors, who collectively purchased the 2,000,000 newly issued shares.

What are the terms of the newly issued Encision shares?

The company issued 2,000,000 common shares at a price of $0.04 per share. The shares are restricted and do not have registration rights.

What will Encision use the private placement proceeds for?

The company stated that the $80,000 in proceeds will be used for general working capital purposes.